[go: up one dir, main page]

CU20120071A7 - DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA - Google Patents

DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA

Info

Publication number
CU20120071A7
CU20120071A7 CU2012000071A CU20120071A CU20120071A7 CU 20120071 A7 CU20120071 A7 CU 20120071A7 CU 2012000071 A CU2012000071 A CU 2012000071A CU 20120071 A CU20120071 A CU 20120071A CU 20120071 A7 CU20120071 A7 CU 20120071A7
Authority
CU
Cuba
Prior art keywords
useful
pirazoloespirocetone
acetil
derivatives
coa carboxylase
Prior art date
Application number
CU2012000071A
Other languages
English (en)
Other versions
CU24077B1 (es
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20120071A7 publication Critical patent/CU20120071A7/es
Publication of CU24077B1 publication Critical patent/CU24077B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un compuesto de Fórmula (1): ESPACIO PARA LA FÓRMULA en la que R1, R2, R3 y R4 son como se describen en el presente documento; los cuales son útiles en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una(s) enzima(s) acetil-CoA carboxilasa(s) en un animal.
CU2012000071A 2009-11-10 2010-10-29 DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA CU24077B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Publications (2)

Publication Number Publication Date
CU20120071A7 true CU20120071A7 (es) 2013-05-31
CU24077B1 CU24077B1 (es) 2015-03-30

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000071A CU24077B1 (es) 2009-11-10 2010-10-29 DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA

Country Status (40)

Country Link
US (4) US8288405B2 (es)
EP (3) EP2947082A1 (es)
JP (1) JP5114610B1 (es)
KR (2) KR101550557B1 (es)
CN (1) CN102695708B (es)
AP (1) AP3283A (es)
AR (1) AR078944A1 (es)
AU (1) AU2010317501B2 (es)
BR (1) BR112012011072A2 (es)
CA (1) CA2778886C (es)
CL (1) CL2012000999A1 (es)
CO (1) CO6541569A2 (es)
CR (1) CR20120190A (es)
CU (1) CU24077B1 (es)
DK (1) DK2499139T3 (es)
DO (1) DOP2012000128A (es)
EA (1) EA020153B1 (es)
EC (1) ECSP12011880A (es)
ES (1) ES2444543T3 (es)
GE (1) GEP20146169B (es)
HK (1) HK1173724A1 (es)
HN (1) HN2012000973A (es)
HR (1) HRP20140025T1 (es)
IL (1) IL219373A (es)
MA (1) MA33734B1 (es)
MX (1) MX2012005429A (es)
NI (1) NI201200089A (es)
NZ (1) NZ599815A (es)
PE (1) PE20121469A1 (es)
PH (1) PH12012500903A1 (es)
PL (1) PL2499139T3 (es)
PT (1) PT2499139E (es)
RS (1) RS53156B (es)
SI (1) SI2499139T1 (es)
TN (1) TN2012000192A1 (es)
TW (1) TWI394756B (es)
UA (1) UA102336C2 (es)
UY (1) UY33020A (es)
WO (1) WO2011058474A1 (es)
ZA (1) ZA201204231B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724774C (en) 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
KR101550557B1 (ko) 2009-11-10 2015-09-04 화이자 인코포레이티드 N1-피라졸로스피로케톤 아세틸-coa 카복실라아제 억제제
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012042433A1 (en) 2010-09-30 2012-04-05 Pfizer Inc. N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
DK2632925T3 (en) 2010-10-29 2015-06-29 Pfizer N1 / N2-lactam acetyl-CoA carboxylase inhibitors
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CN106117205B (zh) * 2011-04-22 2018-09-21 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
EP2969007B1 (en) 2013-03-14 2019-05-08 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
RU2016106829A (ru) 2013-09-12 2017-10-17 Пфайзер Инк. Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей
WO2015056782A1 (ja) 2013-10-17 2015-04-23 塩野義製薬株式会社 新規アルキレン誘導体
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2911292T3 (es) 2014-09-16 2022-05-18 Celgene Quanticel Res Inc Inhibidores de desmetilasas de histonas
SG11201702119PA (en) * 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
CA2966834C (en) 2014-11-10 2022-08-30 National University Corporation Yokohama National University Oxygen-generating anode
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds
FI3713942T3 (fi) 2017-11-21 2023-05-04 Pfizer 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
WO2021235508A1 (ja) 2020-05-21 2021-11-25 塩野義製薬株式会社 脂肪性肝疾患の治療用医薬
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
WO2024023727A1 (en) * 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO2002068388A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE303178T1 (de) 2002-02-27 2005-09-15 Pfizer Prod Inc Acc-hemmer
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
CN1950374A (zh) 2004-05-25 2007-04-18 辉瑞产品公司 四氮杂苯并[e]甘菊环衍生物及其类似物
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007011809A1 (en) 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
CA2629406A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
RS20090249A (en) * 2006-11-29 2010-06-30 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibotors
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2009010951A (es) * 2007-04-12 2009-10-29 Pfizer Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c.
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724603A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2724774C (en) * 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
AU2009271634A1 (en) * 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
ES2652289T3 (es) * 2008-09-18 2018-02-01 Auspex Pharmaceuticals, Inc. Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2
EP2499140A1 (en) 2009-11-10 2012-09-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
KR101550557B1 (ko) * 2009-11-10 2015-09-04 화이자 인코포레이티드 N1-피라졸로스피로케톤 아세틸-coa 카복실라아제 억제제
WO2012042433A1 (en) * 2010-09-30 2012-04-05 Pfizer Inc. N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
CN106117205B (zh) * 2011-04-22 2018-09-21 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物

Also Published As

Publication number Publication date
HN2012000973A (es) 2015-03-02
US8802690B2 (en) 2014-08-12
IL219373A0 (en) 2012-06-28
US8288405B2 (en) 2012-10-16
NI201200089A (es) 2012-08-20
EP2947082A1 (en) 2015-11-25
CR20120190A (es) 2012-05-24
WO2011058474A8 (en) 2012-04-26
HK1173724A1 (en) 2013-05-24
EP2499139B1 (en) 2013-12-11
ZA201204231B (en) 2013-02-27
AP3283A (en) 2015-05-31
DK2499139T3 (da) 2014-01-27
PT2499139E (pt) 2014-02-10
AR078944A1 (es) 2011-12-14
US9139587B2 (en) 2015-09-22
KR101550557B1 (ko) 2015-09-04
MX2012005429A (es) 2012-06-19
CN102695708B (zh) 2014-10-15
UY33020A (es) 2011-06-30
CA2778886A1 (en) 2011-05-19
CA2778886C (en) 2014-01-07
CL2012000999A1 (es) 2012-07-20
KR20140034919A (ko) 2014-03-20
UA102336C2 (uk) 2013-06-25
EP2676958A1 (en) 2013-12-25
AP2012006269A0 (en) 2012-06-30
EA020153B1 (ru) 2014-09-30
MA33734B1 (fr) 2012-11-01
ES2444543T3 (es) 2014-02-25
PE20121469A1 (es) 2012-11-01
JP2013510192A (ja) 2013-03-21
PH12012500903A1 (en) 2014-09-24
ECSP12011880A (es) 2012-07-31
KR101478517B1 (ko) 2015-01-02
EA201290191A1 (ru) 2012-12-28
AU2010317501B2 (en) 2013-06-06
TWI394756B (zh) 2013-05-01
SI2499139T1 (sl) 2014-01-31
CO6541569A2 (es) 2012-10-16
CU24077B1 (es) 2015-03-30
JP5114610B1 (ja) 2013-01-09
NZ599815A (en) 2013-04-26
TW201127838A (en) 2011-08-16
KR20120099460A (ko) 2012-09-10
PL2499139T3 (pl) 2014-04-30
US8507681B2 (en) 2013-08-13
BR112012011072A2 (pt) 2017-06-20
CN102695708A (zh) 2012-09-26
TN2012000192A1 (fr) 2013-12-12
RS53156B (en) 2014-06-30
EP2676958B1 (en) 2015-07-01
WO2011058474A1 (en) 2011-05-19
US20130296319A1 (en) 2013-11-07
EP2499139A1 (en) 2012-09-19
AU2010317501A1 (en) 2012-05-17
US20110111046A1 (en) 2011-05-12
US20140288111A1 (en) 2014-09-25
DOP2012000128A (es) 2012-08-31
US20130030181A1 (en) 2013-01-31
HRP20140025T1 (hr) 2014-02-14
GEP20146169B (en) 2014-09-25
IL219373A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
GT200600197A (es) Compuestos y composiciones como inhibidores de proteina quinasa
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
NI201000157A (es) Inhibidores desacetilasas b a base de hidroxamato.
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
NI201100035A (es) Agentes antifúngicos.
ECSP088988A (es) Derivados de ácido fenilacético
CY1114907T1 (el) N1-πυραζολοσπειροκετονης αναστολεις ακετυλ-coa καρβοξυλασης
GT200600477A (es) Inhibidores de integrasa de vih

Legal Events

Date Code Title Description
FG Grant of patent